neoSurgical Limited Begins Postmarket Surveillance Study Of FDA-Cleared NeoClose Versus Standard Of Care For Closing Port Site Incisions In Lap And Robotic Surgeries

NEWTON, Mass.--(BUSINESS WIRE)--neoSurgical Inc. announced today that it has begun a Postmarket Surveillance Study of its FDA-cleared device, neoClose®, at University of Texas Health Sciences Center at Houston. The randomized study will compare neoClose® against the standard of care for closure in a bariatric surgery gastric bypass population of 70 adults aged 18-70 years with BMI > 35.